newsfilter
← Latest News
Business Wire·

Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201

Data show promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma Full data readout of Phase 1 study expected in Q1 2024 Gamida Cell Ltd. (NASDAQ:GMDA), a